Drug side effects
nalbuphine Side Effects
The reactions most often reported to the FDA for nalbuphine (also sold as Nubain), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 218
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2007 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of nalbuphine come from 218 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 218 reports to the FDA Adverse Event Reporting System (FAERS) for nalbuphine (Nubain): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
218
Reports Mentioning Death
10
4.6% of reports — not proof the medicine caused the death
Hospitalizations
77
35.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 10 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 2 |
| CONTUSION | 2 |
| HYPERTENSION | 2 |
| HYPOTENSION | 2 |
| RENAL IMPAIRMENT | 2 |
| RESPIRATORY FAILURE | 2 |
| ANAEMIA | 1 |
| ANAPHYLACTOID REACTION | 1 |
| AREFLEXIA | 1 |
| B-CELL TYPE ACUTE LEUKAEMIA | 1 |
| BACK PAIN | 1 |
| BLINDNESS UNILATERAL | 1 |
| BLISTER | 1 |
| BRAIN MIDLINE SHIFT | 1 |
| BRAIN OEDEMA | 1 |
| CANDIDA SEPSIS | 1 |
| CAPILLARY LEAK SYNDROME | 1 |
| CARDIO-RESPIRATORY ARREST | 1 |
| CEREBRAL HAEMORRHAGE | 1 |
| CHRONIC KIDNEY DISEASE | 1 |
Reactions in Hospitalization Reports
Top reactions in 77 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ACUTE HEPATIC FAILURE | 6 |
| PANCREATITIS ACUTE | 6 |
| FEBRILE BONE MARROW APLASIA | 4 |
| MENTAL STATUS CHANGES | 4 |
| PYREXIA | 4 |
| CARDIAC PERFUSION DEFECT | 3 |
| DRUG CLEARANCE DECREASED | 3 |
| FATIGUE | 3 |
| HAEMODYNAMIC INSTABILITY | 3 |
| INTRA-ABDOMINAL HAEMORRHAGE | 3 |
| RESPIRATORY FAILURE | 3 |
| ACUTE KIDNEY INJURY | 2 |
| AGRANULOCYTOSIS | 2 |
| AMNESIA | 2 |
| ANAEMIA | 2 |
| ASPARTATE AMINOTRANSFERASE INCREASED | 2 |
| ASTHENIA | 2 |
| BRADYCARDIA | 2 |
Nearby, Related Medications
What the FAERS Data Reveals About nalbuphine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 218 voluntary reports linked to nalbuphine and its brand equivalents (Nubain), spanning 2007 through 2025. Of those, 10 (4.6%) listed death as an outcome and 77 (35.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 69% were female and 31% male; age distribution skews toward 0-17, with 74 reports in that bracket. The single most reported reaction is drug hypersensitivity with 36 submissions, followed by foetal exposure during pregnancy and neonatal asphyxia.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to nalbuphine's 218.
Read our methodology - how this data is sourced, computed, and verified.